Mandate

Vinge advises Industrifonden in connection with its investment in "invisible cycle helmets"

May 27, 2011

Vinge has advised Industrifonden in connection with its investment in Hövding Sverige AB, a company which has developed a revolutionary type of cycle helmet which sits like a collar around the cyclist's neck. The collar contains a compressed airbag which is activated by sensors when an accident occurs.The company has raised new capital amounting to SEK 30 million through a SEK 20 million investment by Industrifonden and an SEK 10 million investment by the existing owners. The funds will be used to finance the launch of the new cycle helmet which will be avialble for sale in the autumn.
 
Industrifonden invests in small and medium sized Swedish companies with the potential for international expansion. The fund has access to approximately SEK 3 billion, SEK 1.5 billion of which is invested in approximately 90 companies within the technology, cleantech, life science and industrial sectors.
 
Vinge's team consisted of Johan Larsson and Johan Winnerblad, who was the responsible partner.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026